Overview

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

Status:
Recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the ration of patients getting an lighten therapeutic strategy after 18F-fluoro-désoxyglucose positron emission tomography (PET-TDM) in grade I (cohort 1) or metastatic (cohort 2) seminoma

Phase:

Phase 2

Details

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Treatments:

Carboplatin
Etoposide
Etoposide phosphate